trending Market Intelligence /marketintelligence/en/news-insights/trending/mu7w5zckdp8dykywbs1w6a2 content esgSubNav
In This List

Luminor Medical changes name to Rise Life Science; appoints CFO, chairman

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Luminor Medical changes name to Rise Life Science; appoints CFO, chairman

Canada's Luminor Medical Technologies Inc. changed its name to Rise Life Science Corp., following its acquisition of Rise Research Inc., a privately held cannabis products developer.

The medical diagnostic company said it will also start trading its shares under the symbol RLSC, subject to Canadian Securities Commission approval.

Anton Mattadeen, Rise Life Science CEO, said the name change reflects its focus on medical cannabis-based formulations.

Mattadeen will serve as the company's chairman, following Harry Bloomfield's retirement.

Meanwhile, Robert Lelovic was appointed Rise Life Science CFO, replacing Chris Carmichael, who served in the position during the company's transition to Rise Life Science. Lelovic is the president of Robert Lelovic Professional Corp., which provides research and consulting services.

Additionally, Rise Life Science COO Chris Dollard, Constance Finley and Michael Campbell joined the company's board.

Dollard was previously Rise Research Inc. COO. Finley is the founder and president of Constance Therapeutics Inc., a privately held cannabis extract producer based in San Francisco. Campbell is general counsel and corporate secretary at Intellipharmaceutics International Inc., which develops novel and generic oral solid dosage drugs.